A recent study, published in Transfusion, analyzed 3 granulocyte-colony-stimulating factor treatments in an attempt to compare the mobilization efficiency of 2 innovator G-CSF treatments with that of 1 biosimilar treatment.
In patients with multiple myeloma (MM) who are eligible for autologous blood stem cell transplantation, high-dose chemotherapy followed by transplantation is standard first-line therapy. After a patient receives 3 to 4 cycles of induction therapy, 1 cycle of mobilization-specific chemotherapy is typically followed by the administration of a granulocyte-colony-stimulating factor (G-CSF) treatment to facilitate the mobilization of peripheral blood stem cells (PBSCs) prior to collection.
A recent study, published in Transfusion, analyzed 3 G-CSF treatments in an attempt to compare the mobilization efficiency of 2 innovator G-CSF treatments with that of 1 biosimilar treatment.
The retrospective study compared the mobilization efficiency of reference filgrastim (Neupogen), lenograstim (Granocyte), and biosimilar filgrastim (Filgrastim Hexal) in a homogeneous group of 250 patients with MM in first-line treatment. Of this group, 30% (n = 73) received the reference filgrastim, 52% (n = 131) received biosimilar filgrastim, and 18% (n = 45) received lenograstim. Each patient received a subcutaneous dose of 5 to 10 µg per kilogram of body weight beginning at day 5 after chemomobilization until the collection of CD34-positive (CD34+) cells was complete.
The study found that there were no significant differences in mobilization of CD34+ cells or in collection yields among the reference filgrastim group (median: 10 CD34+ cells × 106/kg body weight; range: 2.7 to 40.4), the biosimilar filgrastim group (median: 9.9; range: 0.2 to 26.0) and the lenograsim group (median 10.7; range: 3.1 to 27.9). Overall, 249 of the 250 patients reached the collection goal of 2 × 106 CD34+ cells per kilogram of body weight during a median of 1 (range: 1 to 3) collection session.
The researchers concluded that there were no significant differences in PBSC mobilization or in reaching individual collection targets among innovator treatments and the biosimilar treatment in patients with MM.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Annual STADA Report Shows Record Profit Growth for 2023
March 25th 2024Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales growth and billions in profits. The CEO credits the company’s success on their strong company culture and focus for innovation.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.